BioTime and its subsidiary OncoCyte are planning to develop a diagnostic device that detects the presence of various human cancers - PanC-Dx.
PanC-Dx is a antibody-based blood test which can detect bladder, breast, colon, lung, stomach and uterus during routine check-ups.
Initial studies conducted by OncoCyte have demonstrated that PanC-Dx may be useful for detecting various types of cancers.
OncoCyte CEO Joseph Wagner said there is an opportunity for OncoCyte to meet the essential regulatory requirements to receive a European CE Mark for this new class of cancer diagnostics.
BioTime is planning to introduce PanC-Dx in Europe in 2013.